Sign in or Register   Sign in or Register
  |  

Mouse Anti-CDC73 Recombinant Antibody (A097) (CBMAB-AP9846LY)

The product is antibody recognizes CDC73. The antibody A097 immunoassay techniques such as: ELISA, WB.
See all CDC73 antibodies

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat
Clone
A097
Antibody Isotype
IgG2a
Application
ELISA, WB

Basic Information

Immunogen
Fusion protein of HRPT2/CDC73
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG2a
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
Affinity purity
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Cell Division Cycle 73
Introduction
CDC73 (Cell Division Cycle 73) is a Protein Coding gene. Diseases associated with CDC73 include Hyperparathyroidism 2 With Jaw Tumors and Parathyroid Carcinoma. Among its related pathways are Metabolism of proteins and Gene Expression. Gene Ontology (GO) annotations related to this gene include RNA polymerase II core binding.
Entrez Gene ID
Human79577
Mouse214498
Rat304832
UniProt ID
HumanQ6P1J9
MouseQ8JZM7
RatQ4V8C8
Alternative Names
Cell Division Cycle 73; Paf1/RNA Polymerase II Complex Component; Cell Division Cycle Protein 73 Homolog; Hyperparathyroidism 2 Protein; C1orf28; HRPT2; Cell Division Cycle 73, Paf1/RNA Polymerase II Complex Component, Homolog (S. Cerevisiae); Cell Division Cycle 73 Paf1/RNA Polymerase II Complex Component-Like Protein; Cell Division Cycle 73, Paf1/RNA Polymerase II Complex Component, Homolog;
Function
Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors.
Biological Process
Beta-catenin-TCF complex assembly Source: Reactome
Cell cycle Source: UniProtKB-KW
Cellular response to lipopolysaccharide Source: UniProtKB
Endodermal cell fate commitment Source: UniProtKB
Histone H2B ubiquitination Source: UniProtKB
Histone monoubiquitination Source: UniProtKB
mRNA polyadenylation Source: UniProtKB
Negative regulation of apoptotic process Source: Ensembl
Negative regulation of cell population proliferation Source: UniProtKB
Negative regulation of epithelial cell proliferation Source: UniProtKB
Negative regulation of fibroblast proliferation Source: UniProtKB
Negative regulation of G1/S transition of mitotic cell cycle Source: UniProtKB
Negative regulation of myeloid cell differentiation Source: UniProtKB
Negative regulation of transcription by RNA polymerase II Source: UniProtKB
Positive regulation of cell cycle G1/S phase transition Source: UniProtKB
Positive regulation of mRNA 3'-end processing Source: UniProtKB
Positive regulation of transcription elongation from RNA polymerase II promoter Source: GO_Central
Positive regulation of Wnt signaling pathway Source: UniProtKB
Protein destabilization Source: UniProtKB
Protein ubiquitination Source: Reactome
Recruitment of 3'-end processing factors to RNA polymerase II holoenzyme complex Source: GO_Central
Regulation of cell growth Source: Ensembl
Stem cell population maintenance Source: UniProtKB
Transcription by RNA polymerase II Source: Reactome
Transcription elongation from RNA polymerase II promoter Source: GO_Central
Wnt signaling pathway Source: UniProtKB-KW
Cellular Location
Nucleus
Involvement in disease
Hyperparathyroidism 1 (HRPT1): An autosomal dominant disorder characterized by hypercalcemia, elevated parathyroid hormone (PTH) levels, and uniglandular or multiglandular parathyroid hyperplasia, adenomas, and carcinomas.
Hyperparathyroidism 2 with jaw tumors (HRPT2): An autosomal dominant neoplasia syndrome characterized by primary hyperparathyroidism, ossifying fibroma of the maxilla and/or mandible, renal tumor, and uterine tumors. It is associated with increased risk of parathyroid cancer.
Parathyroid carcinoma (PRTC): These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.
PTM
Phosphorylated. Dephosphorylated by PTPN11.

Eliška, S., Rehorkova, P., Vcelak, J., Moravcova, J., Havlinova, B., Gabalec, F., & Cap, J. (2021, May). CDC73 associated primary hyperparathyroidism and essential tremor. In Endocrine Abstracts (Vol. 73). Bioscientifica.

Morotti, A., Forno, I., Verdelli, C., Guarnieri, V., Cetani, F., Terrasi, A., ... & Vaira, V. (2020). The oncosuppressors MEN1 and CDC73 are involved in lncRNA deregulation in human parathyroid tumors. Journal of Bone and Mineral Research, 35(12), 2423-2431.

Guo, J., Su, Y., & Zhang, M. (2020). Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p. Cancer Cell International, 20(1), 1-12.

Lines, K. E., Nachtigall, L. B., Dichtel, L. E., Cranston, T., Boon, H., Zhang, X., ... & Thakker, R. V. (2020). Multiple Endocrine Neoplasia Type 1 (MEN1) phenocopy due to a cell cycle division 73 (CDC73) variant. Journal of the Endocrine Society, 4(11), bvaa142.

Yu, F. Q., Wang, Z., Wang, X. W., Wang, S. L., Li, X. D., Huang, Q. S., & Lin, J. H. (2019). MicroRNA‑885‑5p promotes osteosarcoma proliferation and migration by downregulation of cell division cycle protein 73 homolog expression. Oncology letters, 17(2), 1565-1572.

Lines, K., Nachtigall, L., Dichtel, L., Cranston, T., Khairi, S., Boon, H., ... & Thakker, R. (2019). MON-335 Phenocopy of multiple endocrine neoplasia type 1 (MEN1) due to a germline cell division cycle 73 (CDC73) variant. Journal of the Endocrine Society, 3(Supplement_1), MON-335.

Ciuffi, S., Cianferotti, L., Nesi, G., Luzi, E., Marini, F., Giusti, F., ... & Brandi, M. L. (2019). Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity. Endocrine journal, 66(4), 319-327.

Jia, Q., Nie, H., Wan, X., Fu, H., Yang, F., Li, Y., ... & Ni, T. (2018). Down-regulation of cancer-associated gene CDC73 contributes to cellular senescence. Biochemical and biophysical research communications, 499(4), 809-814.

Lines, K. E., Nachtigall, L. B., Dichtel, L. E., Cranston, T., Khairi, S., Boon, H., ... & Thakker, R. V. (2017, October). Multiple endocrine neoplasia type 1 (MEN1) phenocopy due to a P. Leu380Phe cell division cycle 23 (CDC73) mutation. In Endocrine Abstracts (Vol. 50). Bioscientifica.

Walls, G. V., Stevenson, M., Lines, K. E., Newey, P. J., Reed, A. A., Bowl, M. R., ... & Thakker, R. V. (2017). Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome. Oncogene, 36(28), 4025-4036.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CDC73 Recombinant Antibody (A097)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare